# US 2024/0254160 A1 · Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254160 A1
- Document ID: US20240254160A1
- Status: Published application
- Kind: A1
- Application number: 18/629,465
- Filed: 2024-04-08
- Published: 2024-08-01
- Earliest claimed: 2021-10-08
- Assignees: Kashiv Biosciences, LLC
- Applicants: Kashiv BioSciences, LLC
- Inventors: Roshan Ganeshlal Upadhyay; Darshana Jiten Maniar; Shivani Singh
- Web page: https://patentgrep.com/patent/US20240254160A1

## CPC

- C07K 1/16: by chromatography
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B01D 15/424: {Elution mode}
- B01J 20/28083: {being in the range 2-50 nm, i.e. mesopores}
- B01J 20/283: based on silica
- C07K 14/70521: {CD28, CD152}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS

## Abstract

The present invention provides an effective High Performance Liquid Chromatography (SE-HPLC) method to separate or resolve the pre-peak, post-peak and main peak of CTLA4-IgG1 fusion protein, where pre-peak resolution is more than 1.3. The invention further provides effective separation and resolution of post peak impurity present in CTLA4 IgG1 protein. Moreover, the present invention also provides the method for the estimation and/or quantification of pre-peak, post-peak and main peak of the protein mixture.

## Claims

### Claim 1

A method for the separation of CTLA4-IgG1 fusion protein mixture comprising CTLA4-IgG1 fusion protein, pre-peak and post-peak impurity thereof, the process comprises;
a) loading the CTLA4-IgG1 fusion protein mixture onto Size Exclusion High Performance Liquid Chromatography (SE-HPLC) column;
b) separating the protein mixture with suitable mobile phase comprising combination of salts at suitable pH more than pI of the fusion protein; wherein the mobile phase maintains flow rate more than 0.3 mL/min;
c) separating the pre-peak impurity and post-peak impurity from the CTLA4-IgG1 fusion protein of interest; wherein the separation has pre-peak resolution is more than 1.3.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the pre-peak, post peak and said CTLA4-IgG1 fusion protein is further quantified at suitable detection absorbance selected from about 214 nm to about 280 nm.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the protein mixture is obtained from harvest, partially purified, substantially purified by any other purification methods.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the protein mixture is obtained from affinity chromatography, preferably protein A chromatography.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the pre-peak impurity is high molecular weight and/or aggregates and post-peak impurity is low molecular weight and/or fragments of CTLA4-IgG1.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the mobile phase is selected from sodium phosphate in combination with sodium sulphate, potassium phosphate in combination with potassium chloride, sodium phosphate in combination with potassium chloride, and potassium phosphate in combination with sodium sulphate in suitable concentration selected from about 50 mM to about 150 mM.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the mobile phase is selected from sodium phosphate in combination with sodium sulphate in suitable concentration selected from about 80 mM, about 90 mM, about 100 mM, about 110 mM, and about 120 mM.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the mobile phase comprises salt selected from sodium sulphate, potassium chloride, in suitable concentration selected from about 50 mM to about 150 mM.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the salt concentration is selected from about 80 mM, about 90 mM, about 100 mM, about 110 mM, and about 120 mM.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the suitable pH is about 5.5 to about 7.0, preferably about 6.5 to about 6.7.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the mobile phase is free of sodium chloride, arginine, acetonitrile, TFA, guanidine hydrochloride, urea and formic acid.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the loading of the fusion protein mixture comprises about 30 μg/μl to about 80 μg/μl.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the separation performed at flow rate selected from about 0.4 ml/min, about 0.5 ml/min, and about 0.6 ml/min.

### Claim 14 (depends on 1)

The method according to claim 1, wherein SE-HPLC comprises size exclusion column having silica matrix, pore size selected from about 140 Å to about 290 Å and dimension selected from 150*4.6 mm, 300*7.8 mm.

### Claim 15 (depends on 14)

The method according to claim 14, pore size of the SE-HPLC is 14.5 nm or 145 Å to about 20 nm or 200 Å and dimension 300*7.8 mm.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the size exclusion column is BioSep-SEC-S2000, BioSep-SEC-S3000, BioSep-SEC-S4000.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the peak tailing is from about 0.7 to 1.15.

### Claim 18 (depends on 1)

The method according to claim 1, wherein the pI of CTLA4-IgG1 is less than 6.5.

### Claim 19 (depends on 1)

The method according to claim 1, the pre-peak area and post-peak is not merged or interfered with main peak area.

### Claim 20 (depends on 1)

The method according to claim 1, the purity of fusion protein of interest or main peak more than 98%.
